Paul A. Friedman’s SEC Form 4 filings reveal a pronounced, one-directional pattern: he has sold over $101.7 million in stock across 86 transactions while recording zero open-market purchases. His activity is concentrated in two tickers, with the overwhelming majority of recent trades occurring in Madrigal Pharmaceuticals (MDGL). On January 9, 2026, Friedman executed a dense cluster of 23 sales in MDGL, ranging from roughly $21,800 to $1.27 million per transaction, with the largest individual dispositions exceeding $1.2 million. The cumulative value of that single day’s sales—north of $8.9 million—underscores a consistent liquidation posture rather than an isolated event.
The transaction codes further clarify the nature of the activity. Every recent sale is marked “S,” indicating open-market dispositions, while a single “M” code on the same date reflects an option exercise valued at $4,424—a mechanical step that typically precedes selling shares. Notably, there are no “P” purchases, no “A” grants, and no “G” gifts in the recent window, meaning Friedman’s filings are almost purely monetization events. The lone exception is a June 9, 2026 “A” grant in PRLD (Prelude Therapeutics) valued at $0, which represents compensation rather than a discretionary buy.
Across the full dataset, the bias is unambiguous: $101.76 million in total sales against zero dollars in acquisitions. The absence of any open-market buying, combined with the sheer frequency and size of MDGL sales, signals a sustained reduction in exposure. While the filings do not indicate motive, the pattern is consistent with a shareholder systematically unwinding a large position—likely tied to option exercises or planned liquidity—rather than a signal of conviction in either company’s near-term prospects.
AI-assisted summary